Literature DB >> 26097582

Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.

Ahmad Monabati1, Ali-Reza Sokouti1, Sadat Noori Noori1, Akbar Safaei1, Abd-Rasul Talei2, Shapoor Omidvari3, Negar Azarpira4.   

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group with variable clinical presentation. The exact molecular mechanism is not known why some ductal carcinomas may reach to such a large size but still remains in situ. Although, molecular classification of DCIS lesions and nuclear grading are important for identification of more aggressive lesions but it is not sufficient. Our aim was to examine the expression pattern of immunohistochemical (IHC) markers of ER, PR, HER-2 in palpable DCIS lesions and compare with clinicopathological findings. Our center is referral hospital from South of Iran. Samples were obtained from fifty four patients with a diagnosis of palpable DCIS. Equivocal (2+) case in HER-2 IHC testing was more characterized by chromogenic in situ hybridization. The positive frequency of HER2, ER, and PR was 92%, 48%, and 37% respectively. Palpable DCIS lesions were significantly more HER-2 positive (92%). The DCIS cases were more likely to be of high nuclear grade (grade III) and Her-2 positive cases were more likely to be of high nuclear grade than intermediate grade. All ER negative tumors had high nuclear grade. The Her-2 positivity is suggested as the most important factor responsible for marked in situ proliferation and production of palpable mass.

Entities:  

Keywords:  Ductal carcinoma in situ; Her-2; grading; palpable

Mesh:

Substances:

Year:  2015        PMID: 26097582      PMCID: PMC4466969     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

Review 1.  Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee.

Authors: 
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

2.  Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

Authors:  E B Claus; P Chu; C L Howe; T L Davison; D F Stern; D Carter; M P DiGiovanna
Journal:  Exp Mol Pathol       Date:  2001-06       Impact factor: 3.362

Review 3.  Prognostic and predictive molecular markers in DCIS: a review.

Authors:  Sharon Nofech-Mozes; Jacqueline Spayne; Eileen Rakovitch; Wedad Hanna
Journal:  Adv Anat Pathol       Date:  2005-09       Impact factor: 3.875

4.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

Authors:  C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

5.  Potential value of hormone receptor assay in carcinoma in situ of breast.

Authors:  R Barnes; S Masood
Journal:  Am J Clin Pathol       Date:  1990-11       Impact factor: 2.493

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation.

Authors:  L J Solin; B L Fowble; I T Yeh; M J Kowalyshyn; D J Schultz; M C Weiss; R L Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

9.  Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

Authors:  Sharon Steinman; Jianmin Wang; Patricia Bourne; Qi Yang; Ping Tang
Journal:  Ann Clin Lab Sci       Date:  2007       Impact factor: 1.256

Review 10.  Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.

Authors:  Dirce M Carraro; Eliana V Elias; Victor P Andrade
Journal:  Biosci Rep       Date:  2014-02-01       Impact factor: 3.840

View more
  2 in total

1.  Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS.

Authors:  Goshi Oda; Tsuyoshi Nakagawa; Ayumi Ogawa; Yuichi Kumaki; Tokuko Hosoya; Hitoshi Sugimoto; Toshiyuki Ishiba; Mori Mio; Tomoyuki Fujioka; Kazunori Kubota; Iichiroh Onishi; Hiroyuki Uetake
Journal:  Mol Clin Oncol       Date:  2020-04-27

2.  ColXα1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix.

Authors:  Yihong Wang; Shaolei Lu; Jinjun Xiong; Kamaljeet Singh; Yiang Hui; Chaohui Zhao; Alexander S Brodsky; Dongfang Yang; Grant Jolly; Madhu Ouseph; Christoph Schorl; Ronald A DeLellis; Murray B Resnick
Journal:  J Pathol Clin Res       Date:  2018-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.